Director at MiNK Therapeutics (NASDAQ: INKT) receives RSU board compensation

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Behner Peter reported acquisition or exercise transactions in this Form 4 filing.

MiNK Therapeutics, Inc. director Peter Behner reported stock-based board compensation. He received 1,313 restricted stock units on June 1, 2026 and 1,491 units on March 2, 2026, each convertible into common shares and granted in lieu of cash retainers. The RSUs vest one month after each grant, bringing his direct holdings to 22,919 common shares.

The company noted that the RSUs for Q1 2026 board and committee compensation were not filed on time due to an administrative error.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Behner Peter

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,313	$12.38	$16K
Grant/Award	Common Stock	1,491	$10.90	$16K

Holdings After Transaction: Common Stock — 22,919 shares (Direct, null)

Footnotes (1)

The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

Key Figures

RSU grant March 2, 2026: 1,491 shares at $10.90 RSU grant June 1, 2026: 1,313 shares at $12.38 Shares held after latest grant: 22,919 shares +1 more

4 metrics

RSU grant March 2, 2026 1,491 shares at $10.90 Restricted stock units granted in lieu of cash retainers

RSU grant June 1, 2026 1,313 shares at $12.38 Restricted stock units granted in lieu of cash retainers

Shares held after latest grant 22,919 shares Total MiNK Therapeutics common stock directly owned by Behner

RSU vesting period 1 month RSUs vest one month from each grant date

Key Terms

restricted stock units ("RSUs"), contingent right, cash retainers, board and committee compensation, +1 more

5 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"RSUs, which represent a contingent right to receive one share of Common Stock for each RSU"

cash retainers financial

"The RSUs were received in lieu of cash retainers for board and committee compensation"

board and committee compensation financial

"The RSUs were received in lieu of cash retainers for board and committee compensation"

administrative error other

"Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behner Peter

(Last)

(First)

(Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		A		1,491	A	$10.9⁽²⁾	21,606	D
Common Stock	06/01/2026		A		1,313	A	$12.38⁽¹⁾	22,919	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

	By: /s/ Melissa Orilall, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MiNK Therapeutics (INKT) director Peter Behner report?

Director Peter Behner reported awards of restricted stock units in MiNK Therapeutics common stock. He received 1,491 RSUs on March 2, 2026 and 1,313 RSUs on June 1, 2026, reflecting routine equity compensation rather than open-market buying or selling.

How many MiNK Therapeutics (INKT) shares does Peter Behner hold after these Form 4 grants?

After the reported RSU grants, Peter Behner holds 22,919 shares of MiNK Therapeutics common stock directly. This total includes the shares underlying the recently awarded restricted stock units that were granted as part of his board and committee compensation package.

Were the MiNK Therapeutics (INKT) RSUs granted to Peter Behner part of cash compensation?

The RSUs were granted in lieu of cash retainers for board and committee compensation at MiNK Therapeutics. Each restricted stock unit represents a contingent right to receive one share of common stock instead of receiving those board fees in cash.

When do Peter Behner’s MiNK Therapeutics (INKT) RSU grants vest?

The restricted stock units granted to Peter Behner vest one month from their respective grant dates. This means each RSU award converts into MiNK Therapeutics common shares shortly after issuance, assuming the applicable short vesting period is satisfied.

Why does the MiNK Therapeutics (INKT) Form 4 mention an administrative error?

The Form 4 notes that, due to an administrative error, RSUs relating to Q1 2026 board and committee compensation were not filed in a timely manner. This explanation clarifies why the earlier compensation-related equity award appears in the same disclosure.